Q&A: Page 2
Exclusive interviews with industry leaders
-
A CEO’s quest to solve a 400-year-old medical mystery — and he’s also a patient
The CEO of Ventoux Biosciences has the disease that his company is aiming to treat, and it's driving him to find better medications.
Taren Grom • May 1, 2023 -
5 minutes with — DTRA’s Dr. Amir Kalali
An industry veteran, innovator and curator, Dr. Amir Kalali discusses the high points of his career and his go-to productivity hack.
Taren Grom • April 28, 2023 -
Cure Ventures has $350M to pour deep into biotech ‘company building’
The biotech venture capital firm Cure Ventures, led by three industry veterans, raised the inaugural fund in early April and will soon announce its seed companies.
Michael Gibney • April 20, 2023 -
Depression has long been treated chronically — Sage wants to change that
Sage Therapeutics is planning a launch of its newest med, and its chief business officer explains how it could upend the way depression has long been treated.
Michael Gibney • April 18, 2023 -
5 minutes with — Genlantis Diagnostics’ Ahsan Awan
A serial entrepreneur, futurist and industry disrupter, the VP of clinical development and digital health is always on the quest to build a “better mousetrap.”
Taren Grom • April 14, 2023 -
5 minutes with — Parexel’s Peyton Howell
The company’s chief operating and growth officer on her personal quirks and why every pharma leader should read "Getting Naked."
Taren Grom • April 7, 2023 -
Amgen’s aim for a ‘moonshot’ in cardiovascular disease
A VP of global development at Amgen explains how treating general medicine diseases could one day resemble approaches in oncology.
Taren Grom • April 5, 2023 -
Digital biomarkers lay the groundwork for precision medicine beyond the bloodwork
Biomarkers are the hidden talent behind precision medicine, and finding them doesn't have to always come from a blood test — digital pioneers are finding another way.
Michael Gibney • March 30, 2023 -
This GSK clinical data leader embraces the ‘Rubik’s cube’ problem: solving for all sides at once
The clinical data space is rapidly changing the face of the industry, GSK's Mayank Anand said — and the way organizations adopt technology is a critical part of the equation.
Michael Gibney • March 23, 2023 -
Babson aims to shed Theranos curse with new blood testing tech
Babson Diagnostics is trying to create a less invasive blood testing technology — can it gain trust in the post-Theranos era?
Kelly Bilodeau • March 13, 2023 -
IQVIA’s OG of data analytics on the latest clinical trial trends
IQVIA Institute’s Murray Aitken is the man behind the numbers, and here, shares the newest findings on clinical trial burnout, diversity and more.
Taren Grom • March 10, 2023 -
While many leverage precision medicine, Faeth is banking on precision nutrition to tackle cancer
The San Francisco-based biotech is pairing metabolically-engineered diets with existing therapies to starve and kill tumors.
Karissa Waddick • March 9, 2023 -
The ‘recovering academic’ leading Allogene to the next stage of cell therapy
Zachary Roberts joined Allogene at the beginning of this year to lead the company's R&D and bring allogeneic cell therapy to the forefront.
Michael Gibney • March 2, 2023 -
Launched with a ‘pioneer’ in RNA, aTyr Pharma is charting a new course in immunology
With a focus on rare and hard-to-treat diseases, aTyr is banking on its head start in tRNA and vast IP portfolio to build a billion-dollar company.
Taren Grom • March 2, 2023 -
Cytokinetics looks to muscle into the cardiovascular market
With a scientific platform based on muscle biology, the late-stage biotech is addressing cardiovascular and neuromuscular diseases.
Taren Grom • Feb. 24, 2023 -
Why patient care is a public affair
The VP of public affairs at Kyowa Kirin discusses her role in advocating for advocacy.
Taren Grom • Feb. 23, 2023 -
Pheast’s new CEO on how its ‘don’t eat me’ platform could deliver next-gen precision immunotherapies
Jacopo Leonardi’s latest venture is in the burgeoning field of macrophage inhibitors that could target a wide range of cancers.
Taren Grom • Feb. 17, 2023 -
Nectin’s Keytruda combo could fill gaps in immuno-oncology’s treatment paradigm
The Israeli biotech just entered into a collaboration with Merck to develop its own checkpoint inhibitor alongside the bestselling cancer treatment.
Michael Gibney • Feb. 16, 2023 -
Managing for resilience: Passage’s ups and downs in gene therapy
After a rocky year, Passage Bio’s CEO is focused on helping the rare disease specialist bounce back.
Meagan Parrish • Feb. 15, 2023 -
Brian Fox is bringing ‘fresh eyes’ to ad agency Klick
Why the recently appointed president of commercial solutions sees near limitless potential to expand Klick’s footprint across the life sciences — and how generative AI is playing a role.
Karissa Waddick • Feb. 13, 2023 -
Rocket Pharmaceuticals is ready for liftoff in the rare disease space
With two rare disease products on the launch pad for FDA submission in 2023 and a growing pipeline, Rocket is fueled for its next era of growth.
Taren Grom • Feb. 10, 2023 -
Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement
Victoria Richon’s latest venture is in the burgeoning field of protein-enhancing drugs that could target a range of diseases.
Kelly Bilodeau • Feb. 6, 2023 -
Astria Therapeutics’ edge in an ultra-rare disease
With positive early phase data, CEO Jill Milne is aiming to bring an improved preventative option to patients with hereditary angioedema.
Taren Grom • Feb. 1, 2023 -
This biotech CEO secured two billion-dollar Big Pharma deals during the pandemic
With the industry focused on cancer and COVID-19, Marc de Garidel made deals centered on cardio.
Michael Gibney • Jan. 31, 2023 -
Gilead’s commercial chief on why 2023 will be a ‘coming out’ year
With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.
Meagan Parrish • Jan. 26, 2023